Gliflozins in the Management of Cardiovascular Disease | NEJM - nejm.org

Gliflozins — sodium–glucose cotransporter 2 inhibitors — lower blood glucose and glycated hemoglobin in patients with type 2 diabetes without causing hypoglycemia. The agents also improve cardiac function in patients who have heart failure with or without type 2 diabetes and improve renal function, with few adverse effects.

Comments

Post a Comment

Popular posts from this blog

Dyspnea (Shortness of Breath): Causes, Symptoms & Treatment - my.clevelandclinic.org

Image
Overview Shortness of breath (dyspnea) is most commonly caused by heart or lung conditions. Other causes include anemia, anxiety, lack of exercise or living with obesity. What is dyspnea (shortness of breath)? Dyspnea (pronounced "DISP-nee-uh") is the word healthcare providers use for feeling short of breath. You might describe it as not being able to get enough air ("air hunger"), chest tightness or working harder to breathe. Shortness of breath is often a symptom of heart and lung problems. But it can also be a sign of other conditions like asthma, allergies or anxiety. Intense exercise or having a cold can also make you feel breathless. What are paroxysmal nocturnal dyspnea (PND) and sighing dyspnea? Paroxysmal nocturnal dyspnea (PND) is a feeling like you can't breathe an hour or two after falling asleep. Sighing dyspnea is when you sigh a lot after taking deep breaths in to try to relieve the feeling of dyspnea. What is the differ...
Read more

Top pulmonology news from July: FDA updates, antibiotics in cystic fibrosis, treatment of COPD exacerbations - Healio

Image
Top pulmonology news from July: FDA updates, antibiotics in cystic fibrosis, treatment of COPD exacerbations - Healio Top pulmonology news from July: FDA updates, antibiotics in cystic fibrosis, treatment of COPD exacerbations - Healio Posted: 02 Aug 2019 06:01 AM PDT Healio Pulmonology has you covered. The Editors have compiled a list of the most-popular articles posted on Healio Pulmonology in July. See below for links to a study on reducing antibiotic use for COPD exacerbations, the outcome of an FDA advisory committee meeting on nintedanib for a rare form of interstitial lung disease, updates on treatment of respiratory infections in patients with cystic fibrosis and more. C-reactive protein testing safely reduces antibiotic use for COPD exacerbations The use of point-of-care testing for C-reactive protein to guide treatment lessened the use of antibiotics for COPD exacerbations without worsening clinical outcomes, according to a...
Read more

PH Awareness Month Invites People to Discover Pulmonary Hypertension - Pulmonary Hypertension News

Image
PH Awareness Month Invites People to Discover Pulmonary Hypertension - Pulmonary Hypertension News PH Awareness Month Invites People to Discover Pulmonary Hypertension - Pulmonary Hypertension News Posted: 28 Oct 2020 05:00 AM PDT The Pulmonary Hypertension Association ( PHA ) is promoting several events throughout November — the Pulmonary Hypertension (PH) Awareness Month . This year, people are encouraged to discover the risk factors and symptoms of PH, and the challenges faced by those living with the disease, and their families. PH is often underdiagnosed and misunderstood, even among healthcare providers. Being aware of the disease's risk factors may reduce misdiagnoses, advocates say. There is a wide range of risk factors for PH, including other medical conditions such as connective tissue diseases, other lung disorders, or even drug abuse. Lung disorders that increase PF risk include chronic obstructive pulmonary ...
Read more